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ABSTRACT 
 
Coronary heart disease is responsible for more than half of all 
cardiovascular events in individuals less than 75 years of age. Among 
cardiovascular diseases (CVD), acute coronary syndrome is associated with 
substantial morbidity and mortality and places a large financial burden on the 
health care system. The Global Burden of Disease study estimate of age-
standardized CVD death rate of 272 per 100,000 populations in India is higher 
than the global average of 235 per 100,000 populations.
 
The World Health 
Organization (WHO) has estimated that, with the current burden of CVD, India 
would lose $237 billion from the loss of productivity and spending on health care 
over a 10-year period (2005–2015). Drug utilization evaluation of anticoagulant 
drugs is essential considering the spectrum of use and associated risk with their 
therapy. Early risk stratification with the help of various risk scores can assist 
Clinicians in determining appropriate pharmacologic therapies.  
The objectives of the present study were to evaluate anticoagulant use 
patterns, identify and assess various drug interactions and ADRs and also to assess 
the prognostic value of CRUSADE (Can Rapid risk stratification of unstable 
angina patients suppress adverse outcomes with early implementation of the 
ACC/AHA guidelines) risk score in predicting risk of major bleeding among 
patients with acute coronary syndromes (ACS). A total of 122 patients of which 
98 (80%) were males and 24 (20%) were females, from the Cardiology and 
General medicine department as per the inclusion criteria were included in this 
prospective, observational study conducted for duration of 10 months. 
From the study, the mean age of the overall study population was found to 
be 55.63±10.02 and most predominant group was middle adulthood (34-59) 
74(60.65%). Among the ACS patients, ST elevated myocardial infarction 
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103(84.42%) was the most commonly found followed by Unstable angina and 
Non ST elevated myocardial infarction. The most common non modifiable risk 
factor was found to be males 98(80%) and other modifiable risk factors was found 
to be diabetes, hypertension. Diabetes mellitus was the most common co-morbid 
condition among the study populations 30(32.96%). and majority of patients has 
received antiplatelets 242(19.29%) followed by anti-ulcerative agents and 
anticoagulants. A total of 721 drug-drug interactions were identified. 439(60.88%) 
interactions were major in severity. 
Unfractionated heparin 114(96.61%) was found to be most extensively 
prescribed anticoagulants followed by Enoxaparin. More number of patients was 
in the very low bleeding risk category ≥20 (36.88%). The major bleeding risk 
factors were Age (≥65yrs) followed by diabetes, Females etc. Patients at higher 
risk category are also at high risk of bleeding according to CRUSADE risk score. 
The overall incidence of bleeding rates was found to be 8(6.55%). The bleeding 
rate was more in the CRUSADE risk category (>40) (75%) and also in patients 
with ST elevated myocardial infarction (87.5%). 
Across the ACS spectrum, CRUSADE risk score was able to identify 
patients at high bleeding risk and the future aspects of this research study can 
focus on the implementation of various bleeding reducing strategies including the 
dosage adjustments of anticoagulants based on international normalized ratio 
(INR) and activated partial thromboplastin time (ApTT) value, using alternative 
therapy with less bleeding risk, correcting bleeding risk factors, if possible. 
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1. INTRODUCTION 
 
Coronary artery disease or Ischemic Heart disease is a complex chronic 
inflammatory disease, characterized by remodeling and narrowing of the coronary 
arteries supplying oxygen to the heart. Coronary artery disease is the leading 
cause of death and disability worldwide, and its prevalence is expected to increase 
in the coming years.  It can have various clinical manifestations including stable 
angina, acute coronary syndrome, and sudden cardiac death. 
1
Ischemia refers to a 
lack of oxygen due to inadequate perfusion of the myocardium, which causes an 
imbalance between oxygen supply and demand. The term Acute Coronary 
Syndrome refers to any group of clinical symptoms compatible with acute 
myocardial ischemia and includes Unstable angina, Non-ST-segment elevation 
myocardial infarction, and ST-segment elevation myocardial infarction.
 2 
Cardiovascular diseases have now become the leading cause of mortality in 
India. A quarter of all mortality is attributable to CVD. Ischemic heart disease and 
stroke are the world’s biggest killers, accounting for a combined 15 million deaths 
in 2015. These diseases have remained the leading causes of death globally in the 
last 15 years.
 
The Global Burden of Disease study estimate of age-standardized 
CVD death rate of 272 per 100,000 populations in India is higher than the global 
average of 235 per 100,000 populations.
 
The World Health Organization has 
estimated that, with the current burden of CVD, India would lose $237 billion 
from the loss of productivity and spending on health care over a 10-year period 
(2005–2015).3  
The American Heart Association and the American College of Cardiology 
recently updated practice guidelines and performance measures to help clinicians 
adhere to a standard of care for all patients who present with symptoms of ACS. 
Quantitative assessment of risk is useful for clinical decision making. Several 
scores have been developed from different populations to estimate ischemic and 
bleeding risks with different outcomes and time frames. In clinical practice, 
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simple risk scores may be more convenient and preferred. It is recommended to 
use established risk scores for prognosis and bleeding with a class 1 
recommendation.
5
 
 
1.1 ETIOLOGY AND CLASSIFICATION OF ACUTE CORONARY 
SYNDROME 
 
The vast majority of Coronary Heart Disease occurs in patients due to 
atherosclerosis of the coronary arteries. ACS begins when a disrupted 
atherosclerotic plaque in a coronary artery stimulates platelet aggregation and 
thrombus formation. The main coronary arteries are depicted in fig. no: 1. it’s the 
thrombus occluding the vessel that prevents myocardial perfusion. Most cases of 
infarction are due to the formation of an occluding thrombus on the surface of the 
plaque. 
Fig.1.The main coronary arteries of heart 
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The AHA and the ACC recommend that a 12-lead electrocardiogram be 
performed in patients with symptoms consistent with ACS. ST elevation on a 12-
lead ECG in two contiguous leads is diagnostic of STEMI.  With STEMI, T-wave 
inversion may also be present. Electrocardiographic findings reflective of unstable 
angina or NSTEMI include ST-segment depression, inverted T waves and positive 
or negative cardiac markers. Unstable angina and NSTEMI normally result from a 
partially or intermittently occluded coronary artery, whereas STEMI results from 
a fully occluded coronary artery. 
Coronary artery disease leads to the interruption of blood flow to cardiac 
muscle when the arteries are obstructed by plaque. Each artery supplies blood to a 
specific area of the heart. Depending on the degree to which an artery is blocked, 
the tissue that receives blood from it is at risk for ischemia, injury or infarction.  
 If the left anterior descending artery is occluded, the anterior wall of the 
left ventricle, the interventricular septum, the right bundle branch, and the 
left anterior fasciculus of the left bundle branch may become ischemic, 
injured, or infarcted. 
 If the right coronary artery is occluded, the right atrium and ventricle and 
part of the left ventricle may become ischemic, injured, or infarcted. 
  If the circumflex artery is blocked, the lateral walls of the left ventricle, 
the left atrium, and the left posterior fasciculus of the left bundle branch 
may become ischemic, injured, or infarcted.
5
 
 
1.2 RISK FACTORS OF ISCHEMIC HEART DISEASE 
The World Health Organization has recognized obesity, diabetes mellitus, 
hypertension, chronic kidney disease, hypercholesterolemia, and smoking among 
the top10 traditional risk factors for premature death and morbidity.
6 
Traditional Framingham risk factors such as hypertension, hyperlipidemia, 
diabetes, smoking, as well as lifestyle habits such as unhealthy diet and sedentary 
lifestyle are all modifiable. Health care providers should be aware of emerging 
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cardiac risk factors in women such as adverse pregnancy outcomes, systemic 
autoimmune disorders, obstructive sleep apnea, and radiation induced heart 
disease. Psychological factors includes mental stress, depression, anxiety, low 
socioeconomic status, work and marital stress play an important role in Ischemic 
Heart disease in women.
7
 The same was depicted below in Table.1.
 
Table.1. Ischemic Heart Disease risk factors 
 
 
Framingham risk factors 
Hypertension 
Hyperlipidemia 
Smoking 
Peripheral artery disease 
Chronic kidney disease 
 
 
 
 
Non-Framingham risk factors 
Overweight and obesity 
Family history of ischemic heart disease 
Metabolic syndrome: Dysregulation of 
metabolic factors such as tumor necrosis 
factor-α, leptin and adiponectin 
C-reactive protein 
Polycystic ovarian syndrome 
Radiation therapy 
Anemia 
Osteoporosis 
 
Lifestyle factors 
Alcohol 
Physical inactivity etc. 
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1.3 MANAGEMENT OF ACUTE CORONARY SYNDROME 
 
The short-term goals of treatment for the ACS patient are:  
  Early restoration of blood flow to the infarct-related artery to prevent 
infarct expansion (in the case of MI) or prevent complete occlusion 
  Prevention of death and other complications 
  Prevention of coronary artery reocclusion 
  Relief of ischemic chest discomfort 
Either fibrinolysis or immediate primary percutaneous coronary 
intervention is the treatment of choice for reestablishing coronary artery blood 
flow for patients with ST-segment-elevation ACS when the patient presents within 
3 hours of symptom onset. For primary PCI, the patient is taken from the 
emergency department to the cardiac catheterization laboratory and undergoes 
coronary angiography with either balloon angioplasty or placement of a bare 
metal or drug-eluting stent. 
According to the ACC/AHA ST-segment-elevation ACS practice 
guidelines, early pharmacotherapy of ST-segment elevation should include: 
 Intranasal oxygen (if oxygen saturation is <90%) 
 Sublingual followed by intravenous nitroglycerin, aspirin, an IV β-
blocker, unfractionated heparin, and fibrinolysis in eligible candidates. 
 Morphine is administered to patients with refractory angina as an 
analgesic and a venodilator that lowers preload. 
Early pharmacotherapy for non-ST-segment-elevation ACS is similar to that for 
ST-segment-elevation ACS with four exceptions: 
 Fibrinolytic therapy is not administered. 
 Glycoprotein IIb/IIIa receptor blockers are administered to high-risk 
patients for medical therapy as well as for PCI patients. 
 There are no standard quality indicators for patients with non-ST-segment-
elevation ACS who are not diagnosed with MI. 
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1.4 PHARMACOLOGICAL THERAPY  
 
1.4.1 IMMEDIATE CARE TO ALLEVIATE PAIN, PREVENT     
DETERIORATION AND IMPROVE CARDIAC FUNCTION 
Patients with suspected STEMI should receive sublingual Glyceryl 
Trinitrate under the tongue, oxygen administered and intravenous access 
established immediately. If sublingual GTN fails to relieve the chest pain, 
intravenous morphine may be administered together with an antiemetic such as 
prochlorperazine or metoclopamide. 
1.4.2 RESTORING CORONARY FLOW AND MYOCARDIAL TISSUE  
          PERFUSION 
a) Fibrinolytics 
 Administration of a fibrinolytic agent is indicated in patients with ST-
segment-elevation ACS presenting to hospital within 24 hours of the onset 
of chest discomfort who have at least 1 mm of ST-segment elevation in 
two or more contiguous ECG leads. 
 According to ACC/AHA ST-segment-elevation ACS practice guideline, a 
more fibrin-specific agent, such as Alteplase, Reteplase, or Tenecteplase, 
is preferred over a non-fibrin-specific agent, such as Streptokinase. 
 Intracranial hemorrhage and major bleeding are the most serious side 
effects of fibrinolytic agents. The risk of intracranial hemorrhage is higher 
with fibrin-specific agents than with streptokinase. The dose of different 
Fibrinolytic agent is depicted in Table.No.2. 
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Table.2. Dose and Administration of Fibrinolytic agents 
 
b) Percutaneous coronary intervention 
The introduction of primary PCI (angioplasty and/or stent insertion without 
prior or concomitant fibrinolytic therapy) has demonstrated Superiority to 
fibrinolysis. PCIs encompass various invasive procedures to improve myocardial 
blood delivery by opening up the blood vessels. PCIs open stenosed coronary 
vessels and are less invasive than coronary bypass surgery, where the coronary 
vessels are replaced.  
 
 
 
 
 
FIBRINOLYTIC AGENT DOSE AND ADMINISTRATION 
STREPTOKINASE 1.5 million units IV over 60 min 
ALTEPLASE 15 mg IV bolus followed by 0.75 mg/kg IV over 
30 min (max 50 mg) followed by 0.5 mg/kg (max 
35 mg) over 60 min (max dose = 100 mg) 
TENECTEPLASE <60 kg = 30 mg IV bolus 
60–69.9 kg = 35 mg IV bolus 
70–79.9 kg = 40 mg IV bolus 
80–89.9 kg = 45 mg IV bolus 
≥90 kg = 50 mg IV bolus 
RETEPLASE 10 nits IV × 2, 30 min apart 
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A percutaneous (through the skin) transluminal (through the lumen of the 
blood vessels) coronary (into the heart) angioplasty (surgery or repair of the blood 
vessels) was first carried out on a conscious patient in 1977. Now over 2 million 
people a year undergo PCIs. The procedure is less invasive than coronary artery 
bypass graft surgery. PCI involves the passing of a catheter via the femoral or 
radial artery and aorta into the coronary vasculature under radio-contrast 
guidance. Inflation of a balloon at the end of the catheter in the area of the 
atheromatous plaques opens the lumen of the artery.
8, 9
 
 
1.4.3 ANTITHROMBOTIC THERAPY 
 
Current antiplatelet and anticoagulant therapies for acute coronary 
syndromes act on distinct sites in the pathways for platelet activation and 
coagulation. While these therapies are effective in reducing the morbidity and 
mortality associated with ACS, they are associated with a clinically significant 
increase in the risk of bleeding events. Novel therapies that minimize bleeding 
risk while providing protection against thrombotic events may improve outcomes 
in patients with ACS.
10
 The different antithrombotic therapy and their dose was 
depicted in Table.3. 
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Table.3. Adjunctive Antithrombotic Therapy to Support Reperfusion with 
Primary PCI
 11 
 
 
 
 
ANTIPLATELET THERAPY  RECOMMENDATIONS OF 
DOSE AND ADMINISTRATION 
ASPIRIN 162- to 325-mg load before procedure 
75-150 mg maintenance dose 
 P2Y12 INHIBITORS 
CLOPIDOGREL 
PRASUGREL 
TICAGRELOR 
CANGRELOR 
 
600 mg load orally and then 75 mg 
daily 
60 mg load orally and then 10 mg 
daily 
180 mg load orally and then 90 mg 
BD 
30 μg/kg bolus and 4 μg/kg/min 
infusion 
GP IIb/IIIa RECEPTOR ANTAGONISTS 
ABCIXIMAB 
EPTIFIBATIDE 
TIROFIBAN 
 
0.25 mg/kg iv infusion, 0.125 
mcg/kg/min 
180 mcg/kg iv infusion, 2mcg/kg/min 
25mcg/kg iv infusion, 
0.15mcg/kg/min 
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ANTICOAGULANTS RECOMMENDATIONS OF DOSE 
AND ADMINISTRATION 
UFH (UNFRACTIONATED 
HEPARIN) 
Bolus 60 U/kg (max 4000 U) iv, 
infusion 12 U/kg/h (maximum 1000 
U) initially. 
LMWH  
ENOXAPARIN 
 
1mg/kg s.c. BD 
INDIRECT THROMBIN INHIBITOR 
FONDAPARINUX 
 
2.5 mg s.c. OD 
DIRECT THROMBIN INHIBITOR 
BIVALIRUDIN 
 
Bolus 0.75mg/kg iv infusion, 
1.75mg/kg/h 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
 
 
 
Study on anticoagulant utilization evaluation and risk score assessment for predicting bleeding among 
patients with acute coronary syndrome  11 
Fig.2. Targets for antithrombotic drugs 
11
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1.4.4 PREVENTION OF FURTHER INFARCTION OR DEATH 
(SECONDARY PROPHYLAXIS) 
 
a) LIPID-LOWERING AGENTS 
Early initiation (within 24 hours of presentation) of statin therapy is 
recommended in patients with an ACS or Acute Myocardial Infarction, if patients 
are already on statin therapy should continue the therapy. 
 
b) BETA BLOCKERS 
Early Beta blocker administration may help prevent arrhythmias and reduce 
reinfarction, but there is an increased incidence of cardiogenic shock. Current 
ACC/AHA guidelines recommend Beta blockers be initiated orally within the first 
24 hrs after hospitalization. 
Contraindications of Beta blockers 
 Moderate to severe LV failure  
 Pulmonary edema 
 Bradycardia (<60 bpm) 
 Hypotension (SBP<100mmHg) 
 Signs of poor peripheral perfusion 
 Reactive airway disease 
 
c) ANGIOTENSIN-CONVERTING ENZYME INHIBITORS  
 ACE inhibitors and Angiotensin Receptor Blockers have been shown to 
reduce long-term risk of mortality in patients suffering an Acute Myocardial 
Infarction, but there is insufficient evidence to support the routine initiation of 
ACE inhibitors and ARBs in the prehospital or emergency department setting. 
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d) CALCIUM CHANNEL BLOCKERS 
Calcium channel blocking agents have not been shown to reduce mortality 
after acute MI and in certain patients with cardiovascular disease there are data to 
suggest that they are harmful. Beta blockers have been used much more broadly, 
have a much safer profile, and appear to be a more appropriate choice for patients 
presenting with myocardial infarction compared to calcium channel blockers.
12 
 
1.5 DRUG RELATED COMPLICATIONS IN ACUTE CORONARY 
SYNDROME 
 
Dual antiplatelet therapy is currently the standard treatment for acute 
coronary syndrome patients. The use of anticoagulant therapy during primary 
percutaneous coronary intervention is a class 1 indication according to 
international guidelines.
13
The common adverse effects of antiplatelet therapy 
include upper gastrointestinal bleeding, ecchymosis, hematuria, epistaxis and 
ticagrelor- related dyspnea. Severe cases of purpura associated with antiplatelet or 
anticoagulant are characterized by purpura in non exposed parts of the body and 
the mucous membrane that rapidly lead to skin necrosis and signs of 
inflammation. The most common adverse effect associated with antiplatelet agents 
is bleeding, which commonly occurs in GI tract, nose, urinary tract, 
subcutaneous/dermal tissues or at puncture or surgical sites.
14
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1.6 BLEEDING RISK WITH ANTIPLATELETS AND 
ANTICOAGULANTS 
 
Currently, the standard therapy for hospitalized patients with ACS includes 
antiplatelet agents such as including aspirin, P2Y12 inhibitors, glycoprotein 
IIb/IIIa inhibitor in combination with antithrombotic agents unfractionated 
heparin, low molecular weight heparin, direct thrombin inhibitors or anti-Xa 
agents). Balancing the risk of bleeding and thromboembolism is crucial in the 
management of acute coronary syndrome. Several studies demonstrate that the 
risk of bleeding rises with an increased number of antithrombotic agents. Major 
bleeding is a serious complication that is associated with increased morbidity and 
mortality particularly when it occurs after a stent procedure. 
Current ACC/AHA guidelines recommend dual antiplatelet therapy in 
patients with an STEMI for at least 1 year for bare metal stent and drug eluting 
stent. In patient with Unstable angina or NSTEMI receiving a bare metal stent, 
Dual antiplatelet therapy should be given for at least 1 month and preferably for 1 
year. In patients who receive an elective drug eluting stent, the current 
recommendations are for 1 year of dual antiplatelet therapy.
15
 
 
1.7 RISK SCORES IN ACUTE CORONARY SYNDROMES 
 
Risk scores are formula generated numbers used for quantitative risk 
assessment that rank-order individuals according to the likelihood of developing a 
specific outcome (or combination of outcomes) during a defined time interval. 
Risk scores are helpful tools for the assessment of risk in ACS patients. Risk 
scores allow accurate estimations of ischaemic and bleeding risk for individual 
patients.
16
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1.7.1 RISK SCORES FOR ISCHAEMIC RISK ASSESSMENT 
 
Different scores are now available based on initial clinical history, ECG, 
and laboratory tests that enable early risk stratification on admission.
 
The most 
popular ischaemic risk scoring systems in clinical practice have been the TIMI 
risk score, the GRACE risk scores, and, to a lesser extent, the PURSUIT risk 
score. The GRACE score is more advantageous as all its variables are objective 
data. 
TIMI          :    Thrombolysis In Myocardial Infarction 
GRACE     :    Global Registry of Acute Coronary Events 
PURSUIT  :     Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor 
Suppression Using Integrelin Therapy.
16, 17
 
 
The GRACE hospital discharge prediction model for 6-month mortality 
(GRACE score) was developed from a multinational registry involving all subsets 
of ACS including ST-segment elevation myocardial infarction, non–ST-segment 
elevation myocardial infarction, and unstable angina.
18 
The TIMI risk score, defined as the number (zero to seven) of positive 
individual variables, relates to a risk of adverse outcomes ranging from 
approximately 5% to 41% when applied retrospectively to patients studied in large 
NSTE ACS trials.
19
 
 
1.7.2 RISK SCORE FOR BLEEDING RISK ASSESSMENT 
Antithrombotic therapies after coronary intervention reduce ischemic 
events but invariably increase bleeding risk, which in turn may adversely affect 
short and long term outcomes.
 
Hence, it is important to predict the bleeding risk in 
ACS patients in order to modify their treatment aiming to reduce their bleeding 
events and improve their outcome. 
Introduction 
 
 
 
 
Study on anticoagulant utilization evaluation and risk score assessment for predicting bleeding among 
patients with acute coronary syndrome  16 
Many bleeding risk scores have been validated for the prediction of early 
and late bleeding events, and some have been tested on large cohorts with acute 
coronary syndrome, demonstrating reasonably good performance. Among them, 
the CRUSADE score has been validated in 17,857 patients with non–ST segment 
elevation myocardial infarction (MI), and its predictive capability was consistent 
in terms of hemorrhagic risks in patients taking ≥2 antithrombotic medications.20 
 
I. CRUSADE RISK SCORE 
 
The CRUSADE risk score comprises eight characteristics, including 
baseline patient characteristics (gender, history of diabetes, prior vascular 
disease), admission clinical variables (heart rate, systolic blood pressure, and signs 
of congestive heart failure), and admission laboratory values (haematocrit and 
calculated creatinine clearance).  
A history of stroke and peripheral artery disease were considered as prior 
vascular disease according to the CRUSADE registry. These were collected based 
on information from medical records.
21 
The eight predictors range and 
corresponding scores is depicted in Table. No: 4. Each of the variables was 
converted into points, the points were totaled for each patient, and each patient 
was placed in one of five major bleeding risk categories as shown below: 
 Very low (≤20)  
 low (21 to 30)  
 moderate (31 to 40) 
 high (41 to 50) 
 very high (>50)  
Only patients who had completed all of the CRUSADE variables were 
included in the analysis.
22
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Table.4. CRUSADE RISK SCORE – predictors and their scores 
S.NO PREDICTOR RANGE SCORE 
1 BASELINE HEMATOCRIT (%) 
<31 
31-33.9 
34-36.9 
37-39.9 
≥40 
9 
7 
3 
2 
0 
2 CREATININE CLEARANCE 
(ml/min/1.73m
2
) 
>15-30 
>30-60 
>60-90 
>90-120 
>120 
35 
28 
17 
7 
0 
3 DIABETES MELLITUS NO 
YES 
0 
6 
4 SIGNS OF HEART FAILURE NO 
YES 
0 
7 
5 SYSTOLIC BLOOD PRESSURE 
≤90 
91-100 
101-120 
121-180 
181-200 
≥201 
10 
8 
5 
1 
3 
5 
6 HEART RATE 
≤70 
71-80 
81-90 
91-100 
101-110 
111-120 
≥121 
0 
1 
3 
6 
8 
10 
11 
7 PRIOR VASCULAR DISEASE NO 
YES 
0 
6 
8 FEMALE SEX NO 
YES 
0 
8 
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II. HAS-BLED SCORE 
 
HAS-BLED risk score was initially used to access the risk of bleeding in patients 
with atrial fibrillation receiving anticoagulation therapy. Subsequently, clinical 
studies proved that it also has good discriminatory and predictive performance for 
stroke, thromboembolism, MI, and cardiovascular death in patients with AF. 
Recently, some studies have tried to extend its clinical usage in patients 
undergoing percutaneous coronary interventions irrespective of whether or not 
they have AF. 
 
HAS-BLED stratified patients into 3 risk categories as shown below:
 
 Low risk (<2) 
 Intermediate risk (2) 
 High risk (>2).23 
 
III. WILL-BLEED RISK SCORE 
 
Bleeding after cardiac surgery is known to be associated with poor 
outcome, and increased morbidity and mortality due to the need for blood 
transfusion, hypoperfusion- related injuries to critical organs and the need for re-
exploration. Cardiac surgery, especially coronary artery bypass grafting confers a 
huge challenge, as patients are treated with various antithrombotic drugs, which 
are known to increase perioperative risk. Hence identification of patients at high 
risk of bleeding would be of great importance in order to optimize management.  
It includes few variables all easily available in clinical practice: 
antithrombotic therapy, gender, acute coronary syndrome, anaemia, renal 
impairment and critical preoperative state.
24 
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1.8 SIGNIFICANCE OF BLEEDING RISK SCORES IN ACUTE 
CORONARY SYNDROME 
The development of antiplatelet and antithrombotic therapies, in addition to 
invasive therapy has resulted in great improvements in the outcomes of patients 
with acute coronary syndrome but increases the risk of bleeding. The use of risk 
scores can identify patients at increased risk of bleeding and help choose 
medications for treating acute coronary syndrome. Among the bleeding risk scores 
developed, the CRUSADE bleeding score is the most widespread and it should be 
noted that these scores should not limit the use of medication, but help to 
individualize the treatment of acute coronary syndrome. The clinical 
implementation of this risk score can potentially facilitate clinical decision making 
for patient with acute coronary syndrome. 
 
1.9 ROLE OF PHARMACIST IN ACUTE CORONARY SYNDROME  
 
The pharmacist is vital to ensure the delivery of quick, effective and safe 
therapies in the treatment of acute coronary syndrome. Monitoring of each 
therapeutic agent for adequate dosing based on the specific patient parameters of 
age, weight, renal function and liver function will ensure the maximum 
effectiveness of a chosen regimen. Pharmacists are in a unique position to 
measure the quality of care writing and implementing pharmacotherapeutic 
guidelines and measuring the adherence to these guidelines.   
Because many of the drugs used in acute coronary syndrome are associated 
with a risk of bleeding. Therefore the use of international guidelines 
recommended risk scores will help to identify patients at high risk. Dietary 
guidelines, exercise recommendations, counseling on the importance of 
compliance with prescribed regimens are also provided for patients with acute 
coronary syndrome at discharge and can be incorporated into standardized care 
protocols.
25, 26
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2. LITERATURE REVIEW 
 
Zhao et al (2018)
27
 performed a prospective observational study on 
evaluation of CRUSADE and ACUITY- HORIZONS scores for predicting long 
term out of hospital bleeding after percutaneous coronary interventions with drug 
eluting stents in patients receiving dual antiplatelet therapy. They had found that 
2.5% of patients had major bleeding during a 2 year follow up. The calculated risk 
scores by CRUSADE and ACUITY-HORIZONS were significantly higher in the 
major bleeding group than non major bleeding groups. They concluded that the 
value of CRUSADE and ACUITY- HORIZONS scores did not differ 
significantly. 
 
Sanchez-Martinez et al (2017)
28
 conducted a study to assess the predictive 
ability of the CRUSADE risk score in patients with concomitant ACS and chronic 
kidney disease. It was found that Patients with kidney dysfunction had a higher 
CRUSADE bleeding risk score and compared to patients without kidney 
dysfunction. 
 
Bang et al (2017)
29
 conducted a study on CRUSADE score is superior to 
platelet function testing for prediction of bleeding in patients following coronary 
interventions. They compared the performance of the CRUSADE with platelet 
reactivity testing to predict major bleeding events in Korean patients with acute 
coronary syndrome. They concluded that major bleeding events are more common 
in real life than reported in clinical trials. CRUSADE score was superior to 
platelet reactivity testing for predicting short-term bleeding. 
 
Cordero et al (2017)
30
 conducted a study on additive value of the 
CRUSADE score to the GRACE score for mortality risk prediction in patients 
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with acute coronary syndromes. It was found that the addition of the CRUSADE 
score to the GRACE score improved mortality risk estimation. They concluded 
that the CRUSADE score >50 identified patients with higher post-discharge 
mortality and higher hospital mortality. The CRUSADE score improved hospital 
and long-term mortality prediction in patients with GRACE score >140. 
Individual mortality risk estimation should integrate the CRUSADE and GRACE 
scores. 
 
Antoniou et al (2017)
31 
conducted a study on risk scoring to guide 
antiplatelet therapy post-percutaneous coronary intervention for acute coronary 
syndrome. Over the follow-up period, a significant reduction in major adverse 
cardiac event rates between the patients risk score stratified and control was seen. 
They concluded that using appropriate risk scoring to guide antiplatelet therapy 
after ACS is safe and can result in improved clinical outcomes. 
 
Gibbs et al (2016)
32
determined association between the CRUSADE 
bleeding risk score, DAPT regimen and in-hospital bleeding. Patients were sub-
grouped according to DAPT regimen: aspirin with Ticagrelor and aspirin with 
Clopidogrel or Prasugrel. In conclusion, Ticagrelor-based regimen showed lower 
bleeding risk. 
 
Alam et al (2015)
33 
performed a prospective study to evaluate drug 
utilization and the economic impact of anticoagulants for the treatment of unstable 
angina and myocardial infarction. It was found that the data of 487 UA/NSTEMI 
hospitalizations demonstrated that enoxaparin was found to be widely used 
anticoagulant and attributed by 70% of drug utilization comparative to 24.8% 
fondaparinux and 5.1 % dalteparin among private and government Hospitals in 
Karachi. They concluded that fondaparinux remain a choice of drug for the 
treatment of unstable angina/NSTEMI patients by reducing total drug cost. 
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Singh et al (2015)
34
 conducted a prospective, cross sectional study to 
evaluate the drug utilization pattern of anticoagulants, identify and assess drug 
interactions and adverse drug reactions with the use of anticoagulants in a tertiary 
care teaching hospital. It was found that Heparin was mainly used for prophylaxis. 
Enoxaparin and acenocoumarol were other commonly used drugs. 
Acenocoumarol and warfarin were the drugs prescribed at discharge. 35 drug 
interactions were identified and out of this, 16 interactions were severe in 
intensity. 6 adverse drug reactions were also observed during this study. They 
concluded that the pharmacotherapy with anticoagulant drugs should be cost 
effective and with minimum risks involved.  
 
Taha et al (2015)
35
 performed a meta-analysis to evaluate the accuracy of 
different bleeding risk scores for ACS patients. This study has identified Nine 
studies and 13 759 patients. CRUSADE, ACUITY, ACTION and GRACE were 
the scores externally validated. The rate of in-hospital major bleeding was 7.80%, 
2.05% being related to access and 2.70% needing transfusions.  They concluded 
that ACTION, CRUSADE and ACUITY perform similarly to predict risk of 
bleeding in ACS patients. The CRUSADE score is the only one externally 
validated for NSTEMI, while accuracy of the scores increased with radial access. 
 
Ariza-sole et al (2014)
36
 performed a prospective observational study to 
assess the efficacy of bleeding risk scores in elderly patients with acute coronary 
syndromes. Older patients had higher bleeding risk (CRUSADE, 42 vs 22) and a 
slightly higher incidence of major bleeding events (CRUSADE bleeding, 5.1% vs 
3.8%). They concluded that the Current bleeding risk scores showed poorer 
predictive performance in elderly patients with acute coronary syndromes than in 
younger patients. 
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Abu-assi et al (2014)
37
 conducted a review on bleeding risk stratification in 
an era of aggressive management of acute coronary syndrome. Hemorrhagic 
complications occur with a frequency of 1% to 10% during treatment for ACS. 
They performed an update about the ACS bleeding risk scores most frequently 
used in daily clinical practice. This study suggests that CRUSADE score 
represents a useful objective clinical tool which could lead to improvements in 
ACS care. They concluded that using appropriate risk stratification allows 
properly select those patients at increased risk of bleeding, focusing on them the 
efforts to reduce bleeding complications.  
 
Nahar et al (2013)
38
 focused on deriving and validating a genetic bleeding 
risk score based on the genetic and non genetic factors associated with bleeding in 
patients on long term anticoagulant therapy. The genetic bleeding risk score was 
validated to perform better than non genetic bleeding risk score and the sensitivity 
also increased two-folds with genetic bleeding risk score as compared to clinical 
bleeding risk scores.  
 
 
Ariza-sole et al (2013)
39
 performed a prospective study on CRUSADE 
bleeding risk score validation for ST-segment-elevation myocardial infarction 
undergoing primary percutaneous coronary intervention. It was found that the 
rates of in-hospital bleeding across the quintiles of risk groups were 0.4% (very 
low risk), 2.6% (low), 4.6% (moderate), 7.2% (high), and 13.4% (very high) 
(p<0.001). Patients with bleeding events had higher mortality during follow up. 
They concluded that STEMI patients had a significantly lower bleeding risk as 
compared to CRUSADE NSTEMI population. CRUSADE Bleeding Risk Score 
accurately predicted major in-hospital bleeding in this different clinical scenario, 
including patients with radial artery approach. 
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Ariza-sole et al (2013)
40
 conducted a study on is it possible to separate 
ischemic and bleeding risk in patients with non-ST segment elevation acute 
coronary syndromes. It was found that the incidence of major CRUSADE 
bleeding was 27/558 (4.8%). 19 patients (3.4%) died during hospitalization. The 
incidence of death or reinfarction at 30 days was 26/558 (4.99%). A close linear 
relationship was observed between ischemic and bleeding risk scores. They 
concluded that the score that best predicted bleeding complications was the 
GRACE score (designed for predicting ischemic events). Likewise, the score that 
best predicted ischemic events was the ACTION score, which was designed for 
predicting haemorrhagic complications. 
 
Nicolau et al (2013)
41
 conducted a study on the bleeding risk score as a 
mortality predictor in patients with acute coronary syndrome. They calculated the 
ACUITY/HORIZONS bleeding risk score prospectively and retrospectively. In 
conclusion, the bleeding risk score is a very useful and highly reliable predictor of 
in-hospital mortality in a wide range of patients with acute coronary syndrome, 
especially in those with NSTEMI or Unstable angina. 
 
Abu-assi et al (2012)
42
 conducted a study on comparing the predictive 
validity of three contemporary bleeding risk scores in acute coronary syndrome at 
Spain. They calculated the ACTION, CRUSADE, and Mehran et al (2010) 
bleeding risk score and evaluated their performance for predicting major bleeding 
events and thrombolysis in myocardial infarction bleeding episodes, in patients 
with either NSTEMI or STEMI. They concluded that the CRUSADE score was 
found to be the most accurate quantitative tool for NSTEACS and STEMI patients 
undergoing coronary arteriography. 
 
Amador et al (2011)
43 
conducted a study on comparison of ischemic and 
bleeding risk scores in non-ST elevation acute coronary syndromes. There were 
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36 major bleeding events, 34 recurrent ischemic events and 10 deaths. GRACE 
and CRUSADE risk scores demonstrated a better performance than TIMI risk 
score for predicting in-hospital death. They concluded that both ischemic and 
bleeding risk scores are able to predict in-hospital bleeding, ischemic and fatal 
events. 
 
Erdem et al (2011)
44
 conducted a review on assessing the bleeding risk in 
acute coronary syndromes. It was found that CRUSADE, ACUITY-HORIZONS 
and GRACE risk scores developed to predict bleeding risk among ACS patients. 
They concluded that patients at highest risk of bleeding are also at highest risk of 
ischaemic and thrombotic complications. The use of effective treatments with 
lower risks of bleeding may be the preferred choices and the use of 
gastrointestinal protection such as proton pump inhibitors may be helpful.  
 
Kadakia et al (2010)
45
 conducted a study to evaluate anticoagulant use 
patterns and bleeding risk in a contemporary population of patients with acute 
coronary syndrome at 360 US Hospitals. It was found that among STEMI patients, 
unfractionated heparin was most commonly used (66%), followed by bivalirudin 
(14%) and low molecular weight heparin (8%) in NSTEMI patients, 
unfractionated heparin was also the most commonly used anticoagulant (42%), 
followed by low molecular weight heparin (27%) and then bivalirudin (13%). 
More than 50% of patients with either STEMI or NSTEMI were in the 2 lowest 
(≤20 or 21 to 30) of the five CRUSADE bleeding risk groups. More NSTEMI 
patients (33.7%), compared with only 17.3% of STEMI patients, were in the 
highest 2 risk groups (41 to 50 or ≥50). They concluded that the risk of bleeding 
can be evaluated using a simple risk score in both NSTEMI and STEMI, and 
across anticoagulant strategies, providing important prognostic information for the 
clinician. 
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Abu-assi et al (2010)
46
 conducted a study to evaluate the performance 
CRUSADE bleeding score in patients with Non–ST-Segment elevation acute 
myocardial infarction. It was found that a total of 657 patients (84%) were treated 
with ≥2 antithrombotic, of whom 609 (92.7%) underwent cardiac catheterization. 
The overall incidence of major bleeding was 9.5%. This incidence increased with 
the risk category: very low (1.5%), low (4.3%), moderate (7.8%), high (11.8%) 
and very high (28.9%). it showed little capacity to discriminate bleeding risk in 
patients treated with ≥2 antithrombotics who did not undergo cardiac 
catheterization. They concluded that the CRUSADE risk score was generally 
validated and found to be useful in a Spanish cohort of patients treated with or 
without ≥2 antithrombotics and in those treated with or without ≥2 
antithrombotics who underwent cardiac catheterization. 
 
Mehran et al (2010)
47 
conducted a study to develop a practical risk score to 
predict the risk and implications of major bleeding in acute coronary syndromes. 
They concluded that a simple risk score based on 6 baseline measures plus 
anticoagulation regimen identifies patients at increased risk for non coronary 
artery bypass grafting related bleeding and subsequent 1-year mortality, for whom 
appropriate treatment strategies can be implemented. 
 
Subherwal et al (2009)
48
 conducted a study on baseline risk of major 
bleeding in Non-ST-Segment elevation myocardial infarction using the 
CRUSADE bleeding score. Major bleeding was significantly associated with 
lower baseline hematocrit and lower creatinine clearance. They concluded that the 
CRUSADE bleeding score quantifies risk for in-hospital major bleeding across all 
post admission treatments, which enhances baseline risk assessment for NSTEMI 
care.  
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Xavier et al (2008)
49
 described the treatment and outcomes of acute 
coronary syndromes in India. It was found that more patients with STEMI than 
those with NSTEMI were given anti-platelets, ACE inhibitors or ARBs and PCI. 
The 30-day outcomes for patients with STEMI were death, reinfarction and 
stroke. Outcomes for Unstable angina or NSTEMI were better than STEMI. 
Patients in India have a higher rate of STEMI than do patients in the developed 
countries. 
 
Nikolsky et al (2007)
50
 performed a study on development and validation 
of a prognostic risk score for major bleeding in patients undergoing percutaneous 
coronary intervention via the femoral approach. It was found that the risk of major 
bleeding varied from 1.0% in patients without risk factors to 5.4% in high-risk 
patients. They concluded that a simple risk score of baseline clinical and 
procedural variables is useful to predict the incidence of major peri-procedural 
bleeding after contemporary percutaneous coronary intervention using the femoral 
approach. 
 
Cohen (2005)
51
 conducted a review on predictors of bleeding risk and long-
term mortality in patients with acute coronary syndromes. The aim of this review 
was to collate the published evidence on independent predictors of bleeding and 
late mortality in acute coronary syndrome patients, to compare the two sets of risk 
factors, and to investigate whether bleeding is reported as a predictor of late 
mortality. They concluded that the available evidence suggests that any impact of 
bleeding on mortality in ACS patients appears to be confined to the short term, 
and long-term outcomes do not reflect the impact of in-hospital bleeding. 
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3. SCOPE OF THE STUDY 
 
Coronary artery disease is the leading cause of mortality and morbidity in 
the world. Acute coronary syndrome includes unstable angina, Non-ST-Segment 
elevation myocardial infarction and ST-Segment elevation myocardial infarction, 
are the commonest causes of mortality in patients with CAD. The prevalence of 
CAD and the incidence of ACS also are very high among Indians.
52
 
Recurrent ischemic events after an acute coronary syndrome remain 
common. The combined use of antithrombotic agents, antiplatelet agents and 
invasive coronary procedures reduces the risk of ischemic events but also 
increases the risk of bleeding. Not only the bleeding result in an immediate treat, 
but it also associated with an increased coronary artery mortality and reinfarction, 
both in the short and long term adverse outcomes. From the previous studies, 
major bleeding is associated with a 60% increased risk of in-hospital death and 
fivefold increase in one year mortality and reinfarction. These findings have 
brought a paradigm change to risk stratification that takes into account not only 
ischemic risk, but also bleeding risk in the selection of an optimal management 
strategy supported by clinical practice guidelines. Strategies to reduce bleeding 
include:  
 Assessment of bleeding risk in each individual 
 Recognizing early signs of bleeding  
 Using gastro protective agents to reduce gastrointestinal bleeding 
 Appropriate dosing of antithrombotic therapy and minimizing the duration 
of antithrombotics 
 Use of drugs with proven reduced risk of bleeding  
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For the assessment of bleeding risk, various patient-based scoring 
algorithms have been validated for risk stratification in patients referred for 
cardiovascular interventions. The CRUSADE risk score can be used to calculate 
the risk of major bleeding for an individual patient.   Cardiovascular risk scores 
are recommended and should be used for the diagnosis and treatment of 
individuals presenting with both NSTEMI and STEMI, as well as for the 
stratification of all ACS survivors in a long-term follow up.
53, 54, 55, 56, 57 
 
Clinical pharmacists play an essential role in ensuring beneficial outcomes 
for acute coronary syndrome patients by recommending and monitoring therapies 
as outlined in practice guidelines. Therapeutic guidelines recommended of using 
established risk scores to improve the patient outcomes and decreasing the 
readmission rates to the hospital. To determine an acute coronary syndrome 
patient’s level of risk, clinical pharmacist play a key role in calculating bleeding 
and ischemic risk scores using several patient parameters. These prediction scores 
may help physicians stratify patients into categories of increasing risk of bleeding 
so as to evaluate the individual risk/benefit ratio of antithrombotic therapy, either 
prior to starting or during treatment and choose appropriate strategies to reduce 
bleeding risk.
58
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4. OBJECTIVES OF THE STUDY 
 
The proposed study entitled “Study on anticoagulant utilization evaluation and 
risk score assessment for predicting bleeding among patients with acute coronary 
syndrome” includes the following objectives. 
 To evaluate anticoagulant use patterns  
 To assess the prognostic value of CRUSADE (Can Rapid risk stratification 
of unstable angina patients suppress adverse outcomes with early 
implementation of the ACC/AHA guidelines) score in predicting risk of 
major bleeding among patients with acute coronary syndromes (ACS). 
 To monitor the ADR associated with drugs prescribed in ACS.  
 To study the drug interactions in the prescriptions. 
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5. PLAN OF THE STUDY 
 
The proposed study entitled “Study on anticoagulant utilization evaluation and 
risk score assessment for predicting bleeding among patients with acute coronary 
syndrome” was planned and carries out for duration of 10 months and the various 
phases of the study were given below: 
Phase 1 :- (Nov-2017 to Jan-2018) 
 Literature survey to identify the scope of the work. 
 Designing of: 
 Data entry format 
 Patient information and consent form 
 Inclusion and exclusion criteria for data collection. 
 Submission of protocol and obtaining consent from hospital authority 
Phase 2 : - (Feb-2018 to Jun-2018) 
 Data collection through designed standard data entry format during ward 
rounds. 
 Anticoagulant utilization evaluation and risk score assessment. 
 Literature survey (continued) 
 Data analysis. 
Phase 3:- (July-2018 to Aug-2018) 
 Literature survey (continued) 
 Application of statistical tool on the obtained data. 
 Preparation and submission of report. 
 
 
Methodology 
 
 
 
 
Study on anticoagulant utilization evaluation and risk score assessment for predicting bleeding among 
patients with acute coronary syndrome  32 
6. METHODOLOGY 
STUDY SITE 
The proposed study was conducted at a private tertiary care hospital located 
at Coimbatore. It is a 1000 bedded multi-specialty institution where top-flight 
consultants and expertly trained staff offer advanced treatments and procedures 
ranging from advanced neurosurgery to chemotherapy to stem cell transplantation 
to organ transplants and so on. New 230-bed super-specialty block has a high 
staff-patient ratio ensuring that individual attention is at its maximum. The various 
specialties includes Neurosurgery, Cardiology, Diabetology and Endocrinology, 
Neurology, Orthopedics, General surgery, Psychiatry, Pediatrics, Maxillofacial 
surgery, Dentistry, Anesthesiology, Interventional radiology, Psychotherapy, 
Emergency care, Neonatology, ENT, IN Vitro Fertilisation, Dermatology, 
Gastroenterology, Cardiovascular and Thoracic surgery, Nephrology and Urology, 
Pulmonology, Plastic surgery, Oncology, Clinical laboratory, Liver transplant 
unit, Physiotherapy, Haematology, Rheumatology and clinical Immunology, Pain 
Management.   
DEPARTMENT SELECTED FOR STUDY 
The study was conducted in the department of Cardiology General 
Medicine. The reason for the selection of this department was that the preliminary 
ward rounds had revealed a better scope for the study in the department of 
Cardiology and General Medicine. The  prevalence of Cardiovascular diseases 
were found to be more and the department of pharmacy practice provides service 
to the above department and a good co-operation from medical team added up as a 
reason for selecting the department for conducting the present study. The study 
was conducted with expert guidance of the physicians, Clinical Pharmacy 
Professionals and other health care professionals from the study department. 
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CONSENT FROM HOSPITAL AUTHORITIES 
The protocol of the study which included the study background, 
objectives, methodology and probable outcomes was prepared and submitted to 
the Institutional Ethical Committee of the study hospital. The approval from the 
committee was procured through the letter (SRH/EC.12-11/2017-18 dated on 
28
th
 December 2017) and the same was given in Annexure No.1 for reference. 
The author was permitted to utilize the hospital facilities to make a follow up of 
the cases, in the selected departments. All the health care professionals of the 
study site were well informed through Dean’s official circular. 
LITERATURE SURVEY 
The purpose of a literature survey is to gain an understanding of the 
existing research and debates to a particular topic or area of the study, and to 
present that knowledge in the form of a written report. An extensive literature 
survey was carried out regarding the study entitled “STUDY ON 
ANTICOAGULANT UTILIZATION EVALUATION AND RISK SCORE 
ASSESSMENT FOR PREDICTING BLEEDING AMONG PATIENTS WITH 
ACUTE CORONARY SYNDROME”. The literatures supporting the study were 
gathered from various sources includes: 
 Secondary sources 
 International Journal of Cardiology 
 European Society of Cardiology 
 Clinical Cardiology 
 European Heart Journal 
 Journal of American Heart Association 
 Journal of the American College of Cardiology 
 Interventional Cardiology 
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 Journal of Thrombosis Research 
 World Journal of Cardiology 
 Indian Journal of Pharmacy Practice 
 Journal of Pharmacy and Pharmaceutical services 
 Journal of Cardiorenal medicines 
 Chinese Medical Journal 
 Journal of Thrombosis and Homeostasis 
 Journal of Cardiology 
 Journal of Heart, Lung and Circulation 
 Indian Heart Journal 
 Journal of Academic Emergency Medicines 
 Journal of Global burden of Cardiovascular diseases 
 The Lancet 
 Micromedex 
 Tertiary sources 
 
 Dipiro JT, Robert L.Talbert, Gary C. Yees, Barbara G.Wells, 
L.Michael Posey LM. Pharmacotherapy-A Pathophysiologic Approach 
Sixth edition; 2008. p. 291-319. 
 Harrison TR. Harrison’s principles of internal medicine sixteenth 
edition; 2005. P.1434-1459.  
 Walker Roger, Cate Whittlesea. Clinical pharmacy and therapeutics 
fifth edition; 2012. p. 312-332. 
STUDY DESIGN 
A prospective observational study 
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STUDY DURATION 
10 months 
SAMPLE SIZE 
122 patients 
PATIENT SELECTION  
 Inclusion criteria: All inpatients  
 of age ≥ 18, of either sex, 
 having baseline characteristics of CRUSADE risk score 
 Who have been diagnosed to have ST Segment Elevated 
Myocardial Infarction and Unstable Angina/ Non ST Segment 
Elevated Myocardial Infarction, 
 For STEMI and NSTEMI:-Ischemic symptoms at rest lasting ≥10 
min, ECG changes associated with STEMI and positive Cardiac 
markers associated with NSTEMI, 
 For Unstable angina: defined as ischemic chest pain lasting more 
than 30 minutes with no evidence of  ST-elevation, 
 Willing to participate. 
 
 Exclusion criteria: Patients who are,  
 critically ill patients,  
 with insufficient data in their records, 
 Not willing to participate. 
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PATIENT INFORMATION FORM 
 
A patient information form has been prepared to inform the patients and 
care givers of patients about the purpose, necessity of the study assuring them that 
the confidentiality will be strictly maintained and this is for only the betterment of 
patient’s health. The format includes the details like Department address, name 
and signature of the investigator and supervisor, date, place and details of the 
study. The model of the patient information form was given in the Annexure No: 
2 for reference. 
 
 PATIENT CONSENT FORM 
 
A patient consent form has also been prepared to obtain written consent 
from all the patient or bystander and will be included in the study. They will be 
informed about the study using patient consent form. The format contains details 
like address, date, place, provision for signature of the patient or bystander, 
investigator and supervisor. The same was given in the Annexure No: 3 for 
reference. 
 
DATA ENTRY FORMAT 
 
A separate data entry form was designed for collecting the data related to 
patients including patient details like name, age, gender, height, weight, BMI, IP. 
No., date of admission, date of discharge, vital signs (BP, pulse, heart rate), reason 
for admission, past medical history, past medication history, social history and 
allergies. Provision was also given in the format for entry of clinical laboratory 
data (blood counts, liver function test, renal function, electrolytes, and urine 
examination), diagnosis, drug chart, anticoagulant utilization pattern and drug 
interaction chart and any interventions. The data entry format also provides for 
recording bleeding risk category using CRUSADE risk score. The model of a 
patient data entry form was given in the Annexure No.: 4 for reference. 
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MATERIAL AND METHODS 
 
Each patient’s medical record was reviewed. All demographic and clinical 
characteristics were obtained and recorded on admission. Data were collected 
during a regular ward round participation in the department of Cardiology and 
General medicine. Patients who had satisfied the inclusion criteria were included 
in the study. All of the patients signed informed consent for data collection and 
use. Appropriate permission to conduct the study was obtained from the Hospital 
authorities. 
 
Anticoagulant utilization evaluation 
 
The obtained data during the ward rounds were thoroughly analyzed to 
evaluate the utilization of different Anticoagulants and their costs in the General 
and Cardiology ward. The collected data were also screened to check the drug 
interactions using the Micromedex drug data base.    
 
Risk score calculation 
 
The CRUSADE risk score calculated for each patient using prognostic 
variables. The CRUSADE risk score comprises eight characteristics, including 
baseline patient characteristics (gender, history of diabetes, prior vascular 
disease), admission clinical variables (heart rate, systolic blood pressure, and signs 
of congestive heart failure), and admission laboratory values (haematocrit and 
calculated creatinine clearance). Creatinine clearance was estimated with the help 
of Cockroft-Gault formula. These were collected based on information from 
medical records. The laboratory results (creatinine, haemoglobin, haematocrit, and 
platelet count) were also collected. A history of stroke and peripheral artery 
disease were considered as prior vascular disease according to the CRUSADE 
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registry. 
Each of the variables was converted into points, the points were totaled for 
each patient, and each patient was placed in one of five major bleeding risk 
categories: 
 Very low (≤20) 
 Low (21to30) 
 Moderate (31to40) 
 High (41to50) 
 Very high (>50) 
Only patients who had completed all of the CRUSADE variables were included in 
the analysis 
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7. RESULTS 
The work entitled “Study on anticoagulant utilization evaluation and risk 
score assessment for predicting bleeding among patients with acute coronary 
syndrome” was carried out in the department of General medicine and cardiology 
at a 1000 bedded multispecialty hospital. A total number of 122 patients with 
acute coronary syndrome have participated in the study as per the inclusion 
criteria. Data were collected, analyzed and the results are furnished below: 
GENDER DISTRIBUTION  
Among the 122 patients enrolled 98 (80%) were males and 24 (20%) were 
females (Table.No.5, Fig.3). The study results showed that the incidence of ACS 
was more common in males compared to females.  
Table.No.5: Gender distribution 
S.NO GENDER NO OF PATIENTS (n=122) PERCENTAGE (%) 
1 Female 98 80 
2 Male 24 20 
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Fig. 3: Gender distribution 
 
 
AGE CATEGORISATION  
The patients were divided into four groups based on their age group as per 
WHO guidelines (Table.No.6, Fig.4). The mean age of the overall study 
population was 55.63± 10.02. The most predominant group was middle adulthood 
(34-59) which accounts for about 74(60.65%) of the overall study population, out 
of this 67 patients were males and 7 patients were females followed by Later 
adulthood (60-75) which accounts for 43(35.24%), Very old age (>75) which 
accounts for 3(2.45%) and Early adulthood (24-34) which accounts for 2(1.63%). 
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Table.No.6: Age categorization 
S.NO AGE MALE FEMALE NO OF 
PATIENTS 
(n=122) 
PERCENT
AGE (%) 
1 EARLY 
ADULTHOOD 
(24-33) 
2 0 2 1.63 
2 MIDDLE 
ADULTHOOD 
(34-59) 
67 7 74 60.65 
3 LATER 
ADULTHOOD 
(60-74) 
28 15 43 35.24 
4 VERY OLD AGE 
(>75) 
1 2 3 2.45 
 
Fig.4: Age categorization 
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CATEGORIZATION OF ACUTE CORONARY SYNDROME PATIENTS  
The patients in the study population were categorized into STEMI, 
NSTEMI, UA and STEMI+UA (Table.No.7, Fig.5). The categorization reveals 
103(84.42%) patients were ST elevated myocardial infarction and they were most 
prevalent followed by patients with unstable angina 8(6.55%), 6(4.91%) patients 
with STEMI + UA and 5(4.09%) patients with NSTEMI.  
Table.no.7: Categorization of ACS 
S.NO CATEGORY OF 
ACS 
NO OF PATIENTS 
(n=122) 
OVERALL 
PERCENTAGE % 
1 STEMI 103 84.42 
2 UA 8 6.55 
3 STEMI+UA 6 4.91 
4 NSTEMI 5 4.09 
 
Fig.5: Categorization of ACS 
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NUMBER OF VESSELS AFFECTED  
The study population was categorized based on the number of vessels 
affected (Table.No.8, Fig.6). It was found that patients with single vessel disease 
59(48.3%) was more prevalent followed by double vessel disease 44(36.06%) and 
triple vessel disease 19(15.57%). 
Table.no.8: Number of vessels affected 
 
Fig.6 
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S.NO NO.OF VESSELS 
AFFECTED 
NO OF PATIENTS 
AFFECTED (n=122) 
OVERALL 
PERCENTAGE 
(%) 
1 Single vessel disease 59 48.3 
2 Double vessel disease 44 36.06 
3 Triple vessel disease 19 15.57 
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CONCOMITANT DISEASES  
Various co-morbid conditions like hypertension, diabetes mellitus, 
hypothyroidism etc were seen among the study population and many of these were 
found to be risk factors of coronary artery disease. It was observed that 
30(32.96%) of the study population suffered from diabetes mellitus followed by 
25(27.47%) suffered from both diabetes and hypertension, 21(23.07%) suffered 
from hypertension, 5(5.49%) suffered from chronic kidney disease and 
hypothyroidism, 3(3.29%) suffered from stroke and 2(2.19%) suffered from 
congestive heart failure (Table.No.9, Fig.7). 
Table.No.9: Concomitant diseases 
S.NO CONCOMITANT 
DISEASES 
NO OF PATIENTS 
(n=91) 
OVERALL 
PERCENTAGE 
(%) 
1 Diabetes Mellitus 30 32.96 
2 Diabetes and Hypertension 25 27.47 
3 Hypertension 21 23.07 
4 Chronic Kidney diseases 5 5.49 
5 Hypothyroidism 5 5.49 
6  Stroke 3 3.29 
7 Congestive Heart failure 2 2.19 
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Fig.7: Concomitant diseases 
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RISK FACTORS OF ACUTE CORONARY SYNDROME 
The risk factors of ACS were analyzed among the study population. It was 
found that the only non modifiable risk factor was found to be males 98(80%). 
Other important modifiable risk factors was found to be diabetes mellitus 
30(24.59%) followed by both diabetes and hypertension 25(20.49%), 
Hypertension 21((17.21%), smoking and alcoholic 14(11.47%), smoking 
8(6.55%), alcoholic 7(5.73%) and obesity 6(4.91%) (Table.No.10, Fig.8). 
Table.No.10: Risk factors of ACS 
S.NO RISK FACTORS NO OF PATIENTS 
(n=122) 
PERCENTAGE 
(%) 
1 Type 2 diabetes 30 24.59 
2 Diabetes and hypertension 25 20.49 
3 Hypertension 21 17.21 
4 Smoking and alcoholic 14 11.47 
5 Smoking 8 6.55 
6 Alcoholic 7 5.73 
7 obesity 6 4.91 
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Fig.8: Risk factors of ACS 
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NUMBER OF DRUGS PRESCRIBED PER PATIENT  
The total number of drugs prescribed to the study population was found to 
be 1254. The mean number of drugs prescribed per patient was found to be 
11.5±4.18. It was observed that minimum of 5 drugs and maximum of 18 drugs 
were prescribed per patient (Table.No.11, Fig.9).  
Table.No.11: Number of Drugs prescribed per patient 
S.NO NO OF DRUGS 
PRESCRIBED 
NO OF PATIENTS 
(n=122) 
PERCENTAGE 
(%) 
1 5 3 0.02 
2 6 7 5.73 
3 7 8 6.55 
4 8 15 12.29 
5 9 17 13.93 
6 10 16 13.11 
7 11 18 14.75 
8 12 11 9.01 
9 13 10 8.19 
10 14 7 5.73 
11 15 3 2.45 
12 16 5 4.09 
13 17 1 0.81 
14 18 1 0.81 
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Fig.9: No of drugs prescribed per patient 
 
 
THERAPEUTIC CATEGORY OF DRUGS PRESCRIBED  
The drugs prescribed to the study population were analyzed and the 
analysis revealed that majority of the study population has received antiplatelets 
242(19.29%) followed by anti-ulcerative agents 135(10.76%), anticoagulants 
118(9.40%), hypolipidemic agents 114(9.09%), anti-anginal 104(8.29%), anti-
hypertensives 76(6.06%), diuretics 68(5.42%) and Hypoglcemic agents 58(4.62%) 
(Table.No.12, Fig.10). 
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Table.No.12: Therapeutic category of drugs prescribed 
S.NO CATEGORY TOTAL NO 
OF DRUGS 
(n=1254) 
PERCENTAGE 
(%) 
1 ANTIPLATELETS 242 19.29 
2 ANTI-ULCERATIVE AGENTS  135 10.76 
3 ANTICOAGULANTS 118 9.40 
4 HYPOLIPIDEMIC AGENTS 114 9.09 
5 ANTI-ANGINAL 104 8.29 
6 ANTI-HYPERTENSIVES 76 6.06 
7 DIURETICS 68 5.42 
8 HYPOGLYCEMIC AGENTS 58 4.62 
9 NSAIDs ANDANALGESICS 48 3.82 
10 ANTI-EMETICS 44 3.50 
11 STEROIDS 43 3.42 
12 ANTIHISTAMINES 43 3.42 
13 ANTIBIOTICS 34 2.71 
14 VASOPRESSORS 24 1.91 
15 LAXATIVES 14 1.11 
16 SEDATIVES-HYPNOTICS 12 0.95 
17 
ANTI-CHOLINERGICS 
11 0.87 
18 ANTI-ASTHMATICS 10 0.79 
21 THROMBOLYTICS 5 0.39 
27 OTHERS 51 4.06 
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Fig.10 
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DETAILS OF THERAPEUTIC CATEGORY OF DRUGS PRESCRIBED 
Table.N0.13 
ANTI-PLATELETS  
The analysis of details of antiplatelet drugs prescribed revealed that 
majority of the study population has received aspirin 114(47.50%) followed by 
clopidogrel 98(39.25%), ticagrelor 21(8.67%), tirofiban 8(3.30%) and prasugrel 
1(0.41%). 
S.NO NAME OF THE DRUG NO OF 
PATIENTS 
(n=242) 
PERCENTAGE 
(%) 
1 Aspirin 114 47.10 
2 Clopidogrel 98 39.25 
3 Ticagrelor 21 8.67 
4 Tirofiban 8 3.30 
5 Prasugrel 1 0.41 
 
HYPOLIPIDEMIC AGENTS  
The analysis of details of hypolipidemic agents prescribed revealed that the 
majority of study population has received atorvastatin 112(98.24%) followed by 
rosuvastatin 2(1.75%). 
S.NO NAME OF THE DRUG NO OF PATIENTS 
(n=114) 
PERCENTAGE 
(%) 
1 Atorvastatin 112 98.24 
2 Rosuvastatin 2 1.75 
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ANTI-ANGINAL AGENTS  
The analysis of details of the anti-anginal agents prescribed revealed that 
most commonly prescribed were trimetazidine 39(37.5%) followed by isosorbide 
mononitrate 22(21.15%), nitroglycerin 17(16.34%), ivabradine 15(14.42%), 
ranolazine 7(6.73%) and isosorbide dinitrate 4(3.84%).  
S.NO NAME OF THE DRUG NO OF 
PATIENTS 
(n=104) 
PERCENTAGE 
(%) 
6 Trimetazidine 39 37.5 
2 Isosorbide mononitrate 22 21.15 
5 Nitroglycerin 17 16.34 
1 Ivabradine 15 14.42 
4 Ranolazine 7 6.73 
3 Isosorbide dinitrate 4 3.84 
 
ANTI-HYPERTENSIVES  
The analysis of the details of the anti-hypertensives prescribed revealed that 
the most commonly prescribed anti-hypertensives were carvedilol 18(23.68%), 
metoprolol 15(19.73%), nebivolol 11(14.47%). Amlodipine and ramipril was 
found to be used in 10(13.15%) of the patients. Telmisartan was found to be used 
in 6(7.89%) of the patients. 
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S.NO NAME OF THE DRUG NO OF 
PATIENTS 
(n=76) 
PERCENTAGE 
(%) 
1 Carvedilol 18 23.68 
2 Metoprolol 15 19.73 
3 Nebivolol 11 14.47 
4 Amlodipine 10 13.15 
5 Ramipril 10 13.15 
6 Telmisartan 6 7.89 
7 others 6 7.89 
 
DIURETICS 
The analysis of the details of the diuretics prescribed revealed that most 
commonly prescribed were furosemide 33(48.52%) followed by spironolactone 
25(36.76%), torsemide 8(11.76%). Eplerenone and metolozone was found to be 
used in 1(1.47%) of the patients. 
S.NO NAME OF THE DRUG NO OF 
PATIENTS 
(n=68) 
PERCENTAGE 
(%) 
1 Furosemide 33 48.52 
2 Spironolactone 25 36.76 
3 Torsemide 8 11.76 
4 Eplerenone 1 1.47 
5 Metolozone 1 1.47 
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THROMBOLYTICS  
The analysis of the details of thrombolytics prescribed revealed that most 
commonly prescribed were streptokinase 3(60%) followed by nattokinase 2(40%). 
S.NO NAME OF THE DRUG NO OF 
PATIENTS (n=5) 
PERCENTAGE 
(%) 
1 Streptokinase 3 60 
2 Nattokinase 2 40 
 
HYPOGLYCEMIC AGENTS  
The analysis of the details of hypoglycemic agents prescribed revealed that 
majority of the study population has received insulin 38(65.51%) followed by 
metformin 10(17.24%), gliclazide 4(6.89%) and glimepiride 3(5.17%). 
S.NO NAME OF THE DRUG NO OF 
PATIENTS 
(n=58) 
PERCENTAGE 
(%) 
1 Insulin 38 65.51 
2 Metformin 10 17.24 
3 Gliclazide 4 6.89 
4 Glimepiride 3 5.17 
5 others 3 5.17 
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DRUG-DRUG INTERACTIONS 
The medication charts of the study population were analyzed for any drug- 
drug interactions using Micromedex software. It was observed that total number 
of drug interactions was found to be 721. The severity of drug interactions was 
categorized into minor, moderate and major (Table.No.14, Fig.11). Major 
interactions were among the highest 439(60.88%) followed by moderate 
237(32.87%) and minor 45(6.24%). 
SEVERITY OF DRUG-DRUG INTERACTIONS  
Table.No.14: Severity of drug-drug interactions 
 
 
 
 
 
 
 
 
 
 
S.NO SEVERITY OF 
DRUG 
INTERACTION 
NO OF DRUG 
INTERACTIONS 
(n=721) 
OVERALL 
PERCENTAGE 
(%) 
1 MAJOR 439 60.88 
2 MODERATE 237 32.87 
03 MINOR 45 6.24 
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Fig.11: Severity of drug interactions 
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MAJOR DRUG INTERACTIONS  
Table.No.15: List of Major drug interactions 
DRUG 1 DRUG2 NO. 
OF 
INTER
ACTIO
NS 
(n=439) 
EFFECTS INFERENCE 
 
 
 
 
 
 
 
 
 
 
 
Aspirin 
Clopidogrel 89 
Increased risk of 
bleeding 
Monitoring of blood 
counts 
Heparin 104 
Increased risk of 
bleeding 
Evaluate any signs and 
symptoms of blood loss 
Furosemide  25 
 nephrotoxicity Assure diuretic efficacy 
Spironolactone 24 
 nephrotoxicity Assure diuretic efficacy 
Ticagrelor 20 
Increased risk of 
bleeding 
Monitored for signs of 
active bleeding 
Tirofiban 7 
Increased risk of 
bleeding 
Monitored for signs of 
active bleeding 
Metformin 11 
Increased risk of 
hypoglycemia 
Monitor blood sugar 
Torsemide 5 
 nephrotoxicity Assure diuretic efficacy 
Prasugrel 1 
Increased risk of 
bleeding 
Monitored for signs of 
active bleeding 
Enoxaparin 1 
Increased risk of 
bleeding 
Monitored for signs of 
active bleeding 
Piroxicam 1 
Increased risk of 
bleeding 
Giving aspirin 2 hours 
earlier 
Glimepiride 2 
Increased risk of 
hypoglycemia 
Monitor blood sugar 
Aceclofenac 1 
Increased risk of 
bleeding 
Giving aspirin 2 hours 
earlier 
Indomethacin 3 
Increased risk of 
bleeding 
Giving aspirin 2 hours 
earlier 
Digoxin 1 
Prolonged half life 
of digoxin 
Monitoring of serum 
digoxin levels 
 
 
Results 
 
 
 
 
Study on anticoagulant utilization evaluation and risk score assessment for predicting bleeding among 
patients with acute coronary syndrome                                                                                59 
DRUG 1 DRUG 2 NO. EFFECTS INFERENCE 
 
 
Clopidogrel 
Heparin 90 Increased risk of 
bleeding 
Monitored for signs of 
active bleeding 
Amlodipine 7 Decreased 
antiplatelet effects 
Addition of cilastazol 
Enoxaparin 2 Increased risk of 
bleeding 
Monitored for signs of 
active bleeding 
Piroxicam 1 Increased risk of 
bleeding 
Monitored for signs of 
active bleeding 
Ticagrelor 1 Increased risk of 
bleeding 
Monitored for signs of 
active bleeding 
Rabeprazole 1 Reduced 
antiplatelet activity 
Rabeprazole-4 hrs after 
lunch clopidogrel-after 
breakfast 
Diltiazem 1 Reduced 
antiplatelet activity 
Monitoring of blood 
counts 
Indomethacin 2 Increased risk of 
bleeding 
Monitored for signs of 
active bleeding 
Aceclofenac 1 Increased risk of 
bleeding 
Monitored for signs of 
active bleeding 
 
 
 
 
Heparin 
Tirofiban 7 Increased risk of 
bleeding 
Monitored for signs of 
active bleeding 
Enoxaparin 2 Increased risk of 
bleeding 
Monitored for signs of 
active bleeding 
Streptokinase 2 Increased risk of 
bleeding 
Monitored for signs of 
active bleeding 
Aceclofenac 1 Increased risk of 
bleeding 
Monitored for signs of 
active bleeding 
Prasugrel 1 Increased risk of 
bleeding 
Monitored for signs of 
active bleeding 
Piroxicam 1 Increased risk of 
bleeding 
Monitored for signs of 
active bleeding 
Indomethacin 2 Increased risk of 
bleeding 
Monitored for signs of 
active bleeding 
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DRUG 1 DRUG 2 NO. EFFECTS INFERENCE 
Tirofiban Ticagrelor 4 Increased risk of 
bleeding 
Monitored for signs 
of active bleeding 
Rifampicin Isoniazid 1 hepatotoxicity Monitor liver 
function 
Ticagrelor 1 
Decreased 
ticagrelor activity 
Should be avoided 
Ondansetron Tramadol 2 Risk of serotonin 
syndrome 
Closely observe 
patient 
Ivabradine 3 
QT prolongation Use caution 
Diltiazem Atorvastatin 1 Increased risk 
rhbdomyolysis 
Monitor patient for 
any signs 
Nebivolol 1 
Increased risk of 
hypotension 
Monitor BP 
Digoxin Spironolactone 1 Increased 
spironolactone 
exposure 
15% to 30% reduce 
dose of digoxin 
Atorvastatin 1 
Increased digoxin 
concentration 
15% to 30% reduce 
dose of digoxin 
Ranolazine 1 
Increased digoxin 
concentration 
Reduce digoxin dose 
by 30% to 50% 
Alprazolam Fentanyl 1 Increased risk of 
CNS depression 
Adjust dosage 
Metolozone Torsemide 1 Risk of electrolyte 
and fluid balance 
Monitor fluids and 
electrolytes 
Amlodipine Domperidone 1 QT prolongation Administer Lower 
dose of domperidone  
Ivabradine Clarithromycin 1 QT prolongation contraindicated 
Atorvastatin  Clarithromycin 1 Increased risk of 
rhabdomyolysis 
Prefer Pravastatin or 
fluvastatin  
Ranitidine Tramadol 1 Increased tramadol 
exposure-
respiratory 
depression 
Reducing the dose 
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ANTICOAGULANT UTILIZATION EVALUATION 
Drug utilization helps to recognize variability in drug use and to support 
interventions that improve patient outcomes. Anticoagulants are blood thinners, 
usually prescribed to prevent blockage of coronary arteries. In this study it was 
aimed to perform drug utilization evaluation in order to determine appropriate use 
of anticoagulants. 
ANTI-COAGULANTS PRESCRIBED FOR ACUTE CORONARY 
SYNDROME PATIENTS  
Unfractionated heparin was found to be most extensively prescribed 
anticoagulants among the study population 114(96.61%) followed by Low 
molecular weight heparin (Enoxaparin 4(3.38%)) (Table.No.16, Fig.12). 
Table.No.16: Anticoagulants prescribed 
S.NO NAME OF THE DRUG NO OF PATIENTS 
(n=118) 
PERCENTAGE 
(%) 
1 Unfractionated heparin 114 96.61 
2 Low molecular weight 
heparin (Enoxaparin) 
4 3.38 
 
 
 
 
 
 
 
 
Results 
 
 
 
 
Study on anticoagulant utilization evaluation and risk score assessment for predicting bleeding among 
patients with acute coronary syndrome                                                                                62 
Fig.12: Anticoagulants prescribed 
 
 
BLEEDING RISK SCORE ANALYSIS 
The accurate assessment of bleeding risk is to maximize benefits and to 
minimize risk of such complications. It was aimed to calculate CRUSADE 
bleeding risk score among the study population. 
CALCULATION OF BLEEDING RISK SCORE 
The CRUSADE bleeding risk score was calculated for each individual and 
was categorized into Very low, Low, Moderate, High and Very high based on 
CRUSADE bleeding risk score (Table.No.17, Fig.13). The study results revealed 
that 45(36.88%) of the study populations were in the very low bleeding risk 
category (≥20), 33(27.04%) of the study populations were in the low bleeding risk 
category (21-30), 12(9.83%) were in the moderate bleeding risk category (31-40), 
25(20.49%) were in the high bleeding risk (41-50) and 7(5.73%) were in the very  
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high bleeding risk score (>50). It was found that more number of patients were in 
the very low bleeding risk category (≥20).  
CRUSADE BLEEDING RISK SCORE CATEGORY  
Table.No.17: CRUSADE bleeding risk score category 
S.NO CRUSADE 
RISK 
CATEGORY 
RISK 
SCORE 
RANGE 
NO OF 
PATIENTS 
(n=122) 
 
OVERALL 
PERCENTAGE
% 
1 Very low ≥20 45 36.88 
2 Low 21-30 33 27.04 
3 Moderate 31-40 12 9.83 
4 High 41-50 25 20.49 
5 Very high >50 7 5.73 
 
Fig.13: CRUSADE bleeding risk score category 
 
36.88
27.04
9.83
20.49
5.73
0
5
10
15
20
25
30
35
40
≥20 21-30 31-40 41-50 >50
P
E
R
C
E
N
T
A
G
E
 (
%
)
CRUSADE BLEEDING SCORE CATEGORY
CRUSADE BLEEDING 
SCORE CATEGORY
Results 
 
 
 
 
Study on anticoagulant utilization evaluation and risk score assessment for predicting bleeding among 
patients with acute coronary syndrome                                                                                64 
RISK FACTORS FOR BLEEDING IN ACS 
The study populations were analyzed for any bleeding risk factors. It was 
found that most commonly found bleeding risk factors were Age (≥65yrs) 
27(22.13%) followed by Diabetes 26(21.31%), Gender (Female) 24(19.67%), 
Weight (BMI≥25) 24(19.67%), Diabetes and hypertension 22(18.03), Renal 
insufficiency (CrCl≤60ml/min) 19(15.57%), hypertension 19(15.57%) and anemia 
18(14.75%) (Table.No.18, Fig.14). 
Table.No.18: Bleeding risk factors 
S.NO NON MODIFIABLE RISK 
FACTORS 
NO OF 
PATIENTS 
(n=122) 
OVERALL 
PERCENTAGE% 
1 Age (≥65yrs) 27 22.13 
2 Diabetes 26 21.31 
3 Gender (Female) 24 19.67 
4 Weight (BMI≥25) 24 19.67 
5 Diabetes and Hypertention 22 18.03 
6 Renal insufficiency 
(CrCl≤60ml/min) 
19 15.57 
7 Hypertention 19 15.57 
8 Anemia (Male<13g/dl, 
Female<12g/dl) 
18 14.75 
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Fig.14: Risk factors for bleeding 
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The study population was divided into subgroups based on the number of 
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12(9.83%) patients were having 3 bleeding risk factors, 6(4.91%) patients were 
having 4 bleeding risk factors and 5(4.09%) patients were having 5 risk factors 
(Table.No.20, Fig.16). 
Table.No.19: Categorization of patients based on risk factors 
S.NO NO. OF PATIENTS WITH 
BLEEDING RISK FACTORS 
(n=122) (%) 
NO. OF PATIENTS 
WITHOUT BLEEDING RISK 
FACTORS (%)  
1 97(79.50%) 25(20.49%) 
 
Fig.15: Categorization of patients based on risk factors 
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Table.No.20: Number of risk factors for bleeding per patient 
S.NO NO OF RISK 
FACTORS 
NO OF 
PATIENTS 
(n=97) 
OVERALL 
PERCENTAGE (%) 
1 1 41 42.26 
2 2 33 34.02 
3 3 12 12.37 
4 4 6 6.18 
5 5 5 5.15 
 
Fig.16: Number of risk factors for bleeding per patient  
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NO OF RISK FACTORS IN EACH BLEEDING RISK CATEGORY  
The number of risk factors in each bleeding risk category was analyzed for 
individual patient (Table.No.21). The study results showed that patients in very 
high risk of bleeding had more number of risk factors and patients with very low 
bleeding risk category has less number of risk factors. 
Table.No.21: Number of risk factors in each bleeding risk category 
S.NO RISK CATEGORY 
(Based on CRUSADE) 
NO OF RISK FACTORS FOUND (n=122) 
0 1 2 3 4 5 
1 Very low (n=45) 14 20 8 - - - 
2 Low (n=33) 6 16 8 1 2 - 
3 Moderate (n=25) 2 3 13 4 1 - 
4 High (n=12) 2 2 2 6 - 2 
5 Very high (n=7) 1 - 2 1 3 3 
 
CRUSADE SCORE GROUPS AND BLEEDING EVENTS  
Among the study populations, the overall incidence of bleeding rates was 
found to be 8(6.55%). The study population was categorized into groups with no 
bleeding events and bleeding events based on CRUSADE risk score 
(Table.No.22). 101(98.05%) patients in the CRUSADE risk category ≤40 and 
13(68.42%) patients in the CRUSADE risk category >40 were not having any 
bleeding events. The bleeding rate was more in the CRUSADE risk category 
(>40) which accounts for 6(31.57%) as compared to CRUSADE risk category 
(<40) which accounts for 2(1.94%). 
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Table.No.22: CRUSADE score groups and bleeding events 
S.NO CRUSADE 
BLEEDING 
RISK 
CATEGORY 
NO OF PATIENTS 
WITHOUT BLEEDING 
EVENTS (%) 
(n=114) 
NO OF PATIENTS 
WITH BLEEDING 
EVENTS (%) 
(n=8) 
1 CRUSADE ≤40 101(88.5%) 2(25%) 
2 CRUSADE >40 13(11.4%) 6(75%) 
 
Fig.17: CRUSADE score groups and bleeding events 
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ACS CATEGORY AND BLEEDING EVENTS  
The study population was divided into groups with no bleeding events and 
bleeding events based on acute coronary syndrome category (Table.No.23). 
96(93.20%) patients with STEMI, 7(87.5%) with UA, 6(100%)It was found that 
the bleeding rate was more in patients with ST elevated myocardial infarction 7 
(6.79%) followed by Unstable angina 1(12.5%). 
Table.No.23: ACS category and bleeding events 
S.NO ACS 
CATEGORY 
(n=122) 
NO OF PATIENTS 
WITHOUT BLEEDING 
EVENTS (%) (n=114) 
NO OF PATIENTS 
WITH BLEEDING 
EVENTS (%) (n=8) 
1 STEMI 96(84.21) 7(87.5) 
2 UA 7(6.14) 1(12.5) 
3 UA+STEMI 6(5.26) 0(0) 
4 NSTEMI 5(4.38) 0(0) 
Fig.18: ACS category and bleeding events 
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8. DISCUSSION 
 
The work entitled “Study on anticoagulant utilization evaluation and risk 
score assessment for predicting bleeding among patients with acute coronary 
syndrome” was conducted in the department of General Medicine and Cardiology 
at a 1000 bedded multispecialty hospital which has got state of art facilities.  The 
study was undertaken to know the anticoagulant utilization pattern and also to 
predict bleeding risk in the study subjects with acute coronary syndrome with the 
help of a widely accepted CRUSADE risk score. A pilot scale study was 
conducted in the study site to find out the scope of this research.  After ensuring 
the potential of the study, the study protocol was prepared and submitted to the 
Institutional ethical committee and the approval was obtained to carry out this 
research study in the study site.  
A total of 122 patients were enrolled during the study period as per the 
inclusion criteria. The analysis of the study conducted for a period of 10 months 
from November 2017 to August 2018 revealed that there were 98 (80%) male 
patients and 24 (20%) female patients. Our study results correlates to a similar 
study conducted by Seong et al
59
 (2016) reported that coronary artery disease is 
more prevalent in the men than women.  
The age categorizations of the study population revealed that maximum 
number of patient 74(60.65%) are in the age group of middle adulthood (34-59 
years). Our study results correlates with a previous study carried out by Egred M 
et al
60
 (2013) reported that acute myocardial infarction generally more occurs in 
patients older than 45 because of smoking, obesity and lack of physical activity. 
The present study revealed that majority of patients was diagnosed with 
STEMI (84.42%). A study conducted by Bacci M. R et al
61
 (2015) reported that 
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the most prevalent type of ACS was STEMI which correlates with the present 
study. 
A study conducted by Gupta S et al
62
 (2017) concluded that commonest 
non modifiable risk factor was male sex 23(77%) in young adults and 
hypertension, diabetes etc are other modifiable risk factors. The analysis of risk 
factors for ACS in the study population also revealed that the most common non 
modifiable risk factor was found to be males 98(80%). Other common modifiable 
risk factors were found to be diabetes 30(24.59%), hypertension 21(17.21%) and 
smoking 8(6.55%).  
 According to Burke L A et al
63
 (2017) revealed that Diabetes mellitus was 
one of the most prominent co morbid condition found in ACS patients. This result 
was found to be consistent with the present study i.e. major comorbid condition 
suffered by the study population was diabetes mellitus 30(32.96%). 
The analysis of the drugs prescribed to the study population was done 
inorder to describe drug utilization pattern. The most commonly prescribed drug 
category was found to be antiplatelet agents 242(19.29%) followed by 
antiulceratives 135(10.68%), anticoagulants 118(9.40%), hypolipidemics 
114(9.09%) and antianginal drugs 104(8.29%). Our study results correlates with a 
previous study conducted by Rakesh et al
64
 (2016) reported that the major 
prescriptions include antiplatelet agents followed by antianginal drugs.  
 Majority of the present study population were prescribed with dual 
antiplatelet therapy. A similar study conducted by Patti G et al
65
 (2017) revealed 
that current guidelines recommend the use of dual antiplatelet therapy (aspirin 
plus a p2Y12 inhibitor). This reveals the antiplatelet therapy given at the study site 
was appropriate as per the guidelines recommended. 
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Unfractionated heparin 114(96.61%) was found to be most extensively 
prescribed anticoagulant among the study population followed by Enoxaparin 
4(3.38%). This is comparable with the previous study conducted by Kadakia M. 
B et al 
45 
(2010) which reports that unfractionated heparin (66%) was the most 
commonly used anticoagulant. A study conducted by Perez J. L et al
66
 (2012) 
suggests that Enoxaparin is an economically attractive alternative compared with 
UFH. Eventhough the studies suggest the benefit of enoxaparin still the UFH 
widely used in clinical settings. 
Bleeding is the most important complication from acute coronary syndrome 
treatment, especially in patients who are currently on multiple antithrombotic 
therapies. AD Mohamed et al
22
 (2016) concluded that CRUSADE bleeding score 
is a good predictor for major bleeding with acute coronary syndrome and it is 
applicable in both STEMI and UA/STEMI as well as both men and women. Abu 
A et al 
42
 (2012) compared 3 different bleeding risk scores and concluded that 
greatest accuracy obtained with the use of CRUSADE bleeding risk score. So the 
bleeding analysis among the study population was done using CRUSADE risk 
score.  
The CRUSADE bleeding risk score was calculated for each individual and 
was categorized into very low, low, moderate, high and very high bleeding risk 
category. The present study reports that more of the patients were in the very low 
bleeding risk score 45(36.88%) and fewer patients were in the very high bleeding 
risk score 7(5.73%). A study conducted by Kadakia et al
45
 (2010) revealed that 
more patients were in the very low bleeding risk score. A study conducted by Abu 
A et al 
46
 (2014) reported that patients at high and very high bleeding risk 
category are also at increased risk bleeding and appropriate bleeding reducing 
strategies should be implemented in patients with high bleeding risk category. 
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The study population was categorized based on bleeding risk factors. It was 
found that most prevalent bleeding risk factor was Age (≥65yrs). Our study results 
was found to be consistent with a previous study conducted by Manokian S V et 
al 
57
 (2007) showed that patients with major bleeding were older (≥65yrs). 
In the present study, it was found that majority of patients were having 
more than one risk factor, which intensify monitoring of these patients. A study 
conducted by Alhassan M et al 
67 
(2017) concluded that high prevalence of risk 
factors will increases the cardiovascular mortality in ACS patients thus an 
intensive monitoring is required. 
The present study revealed that the overall incidence of bleeding events was 
found to be 8(6.55%) among the study population. A study conducted by Voss 
WB et al 
68
(2016) reported that incidence of bleeding rate was found to be 10.4%.  
Our study results revealed that high numbers of bleeding risk factors were 
found in the patients with very high bleeding risk category. This study results 
correlates with a previous study conducted by  Jinatongthai p et al
21
 (2014) 
conducted a study revealed that there is an increased risk of bleeding with high 
number of risk factors in the higher CRUSADE bleeding risk categories. 
 In the present study, it was found that the more number of bleeding rates 
were in the CRUSADE risk >40 (75%) as compared to CRUSADE risk <40 
2(25%). This study results was consistent with a previous study conducted by 
Subherwal et al
48
 (2009) reported that bleeding rates was more in the high risk 
category and bleeding increases the mortality rate. A study conducted by 
Misumida N et al 
69
(2017) concluded that asian patients with STEMI had 
increased incidence of bleeding events. Similarly our study also reveals 87.5% 
patients with bleeding were belongs to STEMI group. 
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Patients with myocardial infarction are indicated for the combined use of 
anticoagulants and antiplatelet agents which reduces the ischemic risk due to stent 
implantation but increases the risk of bleeding. Inorder to prevent bleeding events, 
continuous monitoring of patients and assessment of bleeding risk score can be 
done. Clinical pharmacist plays a key role in monitoring of bleeding and 
assessment of bleeding risk scores. Calculation of bleeding risk scores and 
assessment of individual bleeding risks enable the health care professionals to 
focus more on the patients with higher bleeding risk category, which inturn 
prevents the morbidity and mortality due to bleeding events. So the present study 
strongly recommends for continuous assessment on bleeding risk for individual 
patient and drug utilization evaluation for updating treatment guidelines for ACS 
patients. 
 
Summary  
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9. SUMMARY 
 
The study entitled “Study on anticoagulant utilization evaluation and risk 
score assessment for predicting bleeding among patients with acute coronary 
syndrome” was carried out in the General medicine and Cardiology ward for a 
period of 10 months as per the inclusion criteria after obtaining consent from the 
Hospital authorities. This study was carried out to predict the bleeding risk of an 
individual subjects with acute coronary syndrome using CRUSADE bleeding risk 
score. The results obtained from the study population are summarized as follows:  
 The study population consisted of 122 patients with acute coronary 
syndrome as per the inclusion criteria. 
 In this study, it was observed that incidence of ACS was more common in 
males 98(80%) than female 24(20%) population. 
 The mean age of the overall study population was found to be 55.63±10.02 
and the most predominant age group was middle adulthood 74(60.65%) 
followed by Later adulthood 43(35.24). 
 The incidence of ST elevated myocardial infarction 103(84.42%) was 
higher as compared to Non ST elevated myocardial infarction 5(4.09%)/ 
Unstable angina 8(6.55%) among the study population. 
 Patients with single vessel disease 59(48.3%) was more common than 
double vessel disease 44(36.06%) and triple vessel disease 19(15.57%). 
 The risk factors of ACS in each individual were identified and it was 
found that most common non modifiable risk factor was males 98(80%). 
Other risk factors includes diabetes 30(24.59%), both diabetes and 
hypertension 25(20.49%), Hypertension 21((17.21%), smoking and 
alcoholic 14(11.47%), smoking 8(6.55%), alcoholic 7(5.73%) and obesity 
6(4.91%) 
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 Analysis of co morbidities among the study population revealed that 
Diabetes mellitus 30(32.9%) and Hypertension 21(23.07%) was the most 
prominent. 
 The most commonly prescribed drug classes were antiplatelets 
242(19.29%) followed by anti-ulceratives 135(10.76%) and anticoagulants 
118(9.40%) 
 The analysis of drug-drug interactions prevailing in the prescription of 
study population had revealed that 439(60.88%) of drug interactions were 
in the major category, 237(32.87%) were in the moderate category and 
45(6.24%) were in the minor category. The total number of drug-drug 
interactions was found to be 721. Most commonly found drug interaction 
were heparin with aspirin (104) which increases the risk of bleeding 
followed by clopidogrel with aspirin. 
 Among the STEMI and NSTEMI, Unfractionated heparin 114(96.61%) 
was the most commonly prescribed followed by Enoxaparin 4(3.38%). 
 The CRUSADE bleeding risk score were calculated for each subject. More 
patients 45(36.88%) in the study populations were in the very low bleeding 
risk category followed by low bleeding risk category 33(27.04%). 
  The analysis of the bleeding risk factors revealed that Age (≥65yrs), 
Diabetes mellitus, gender (females) and weight (BMI ≥25) was most 
commonly found among the study population. 
 Higher numbers of risk factors (5) were found in the very high bleeding 
risk category. 
 The overall bleeding rates were found to be 8(6.55%) and the bleeding 
rates was more in the CRUSADE risk category (>40) and also more in the 
STEMI population as compared to NSTEMI population. 
 
Conclusion 
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10. CONCLUSION 
Risk assessment is important for the fine calculation of the prognosis of 
individual patients, which is an important issue for therapeutic decision making. 
Several trials have shown that antithrombotic drugs and coronary invasive procedures 
can reduce the number of ischemic events in acute coronary syndrome patients, but 
these treatments usually increase the risk of bleeding. Risk of bleeding can be 
evaluated using a simple risk score (i.e. CRUSADE bleeding risk score) in both 
STEMI and NSTEMI and across anticoagulant strategies, providing important 
prognostic information for the Clinician. 
In the present study, the study populations were divided into five groups based 
on CRUSADE bleeding risk score. Based on CRUSADE scores, there was significant 
number of patients were at higher risk for bleeding. The patients with higher risk of 
bleeding require continuous monitoring and patient education inorder to prevent the 
morbidities and mortalities. The drug utilization pattern of anticoagulants reveals the 
more use of UFH at the study site. According to research studies there are many 
anticoagulants with lesser bleeding risk are available. The utilization of safer 
anticoagulants will ensure the lesser events of bleeding. The number of bleeding 
events observed in the study was low, which shows the continuous monitoring and 
prevention of bleeding is ensured at the study site. 
The clinical pharmacist can involve in the assessment of bleeding risk and 
appropriateness of the therapy. The continuous studies are required for the disease 
like ACS which is found to be more prevalent among the Indians. There are many 
factors which can influence the therapy for ACS, thus a proper assessment may result 
in effective and safer therapy in ACS. 
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11. FUTURE OUTLOOK 
 
The present study covers the clinical utility of widely available, guideline-
recommended bleeding risk scores (CRUSADE bleeding risk score). Risk 
stratification with the help of appropriate risk scores is a clinical need pivotal for 
everyday clinical decision making. The future of this research study can focus on 
various bleeding reducing strategies as follows: 
 Personalized, tailored patient therapy based on risk scores 
 Prospective randomized trials (whether novel anticoagulants can be 
combined with anti-platelets will reduce bleeding risks) is suggested. 
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ANTICOAGULANT UTIUZA TION EVALUATION 
s ANTICOAGULANT DOSE FREQUENCY COST/ ALTERNATE COST/ COST 
N GIVEN GIVEN UNIT BRAND UNIT DIFFERENCE 
0 GENERIC BRAND (RS.) (RS.) 
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RISK SCORE ANALYSIS (CRUSADE RISK SCORE) 
S.NO PREDICTOR REFERENCE REFERENCE 
RANGE SCORE 1 BASELINE <31 9 HEMATOCRIT 31-33.9 7 
34-36.9 3 
37-39.9 2 2 CREATININE >15-30 35 
CLEARANCE >30-60 28 
>60-90 17 
>90-120 7 
>120 0 
3 DIABETES MELLITUS NO 0 
YES 6 
4 SIGNS OF HEART NO 0 
FAILURE YES 7 
5 SYSTOLIC BLOOD 91-100 8 
PRESSURE 
_101-120 5 
. . 
121-180 1 
181-200 3 
>201 5 
6 HEART RATE 71-80 1 
81-90 3 
91-100 6 
101-110 8 
111-120 10 
>121 . 11 
7 PRIOR VASCULAR NO 0 
DISEASE YES 6 
8 FEMALE SEX NO 0 
YES 8 
TOTAL SCORE: l5" 
FIVE MAJOR BLEEDING RISK CATEGORIES: 
v/ VERY LOW(~ 20) 
o LOW (21-30) 
o MODERATE (31-40) 
o HIGH (41-50) 
o VERY HIGH (>50) 
Case No: 
OBSERVED OBSERVED 
RANGE SCORE 
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DRUG INTERACTIONS/ADV[ 
RSE DRUG REACTIONS 
DRUG EFFECTS 
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